IP Library Granted Patent US 9,587,265
Granted Patent B2
US 9,587,265 · App. 14/346,284 · Granted Mar 7, 2017

Ubiquitin chain analysis

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,587,265
App. No.
14/346,284
Granted
Mar 7, 2017
Kind
B2
Abstract

There is described a method for analyzing ubiquitin polymers using linkage-specific deubiquitinase enzymes. Novel specificities of deubiquitinase enzymes are also provided.

Claims (15)

1. A method for determining a presence or absence of a linkage type in a polyubiquitin chain, comprising the steps of:

(a) contacting an ubiquitin polymer of unknown linkage type with a first linkage-specific deubiquitinase under conditions in which the enzyme catalyses the disassociation of one or more, but less than seven, ubiquitin linkages;

(b) analysing the product of the catalysis for the presence of lower molecular weight fractions of the ubiquitin polymer;

(c) repeating steps (a) and (b) in the presence of a second, different linkage-specific deubiquitinase; and

(d) identifying the presence or absence of a linkage type cleaved by the first or second deubiquitinase by the presence or absence of lower molecular weight fractions of the ubiquitin polymer in the analysis of step (b).

2. The method according to claim 1 , wherein at least one of the first and second deubiquitinase is an ovarian tumour protease (OTU) family deubiquitinase (DUB).

3. The method according to claim 1 , wherein the deubiquitinase catalyses the dissociation of three, two or one linkage types.

4. The method according to claim 1 , wherein the product of the catalysis reaction is analysed by gel electrophoresis.

5. The method according to claim 1 , wherein the lower molecular weight fractions comprise ubiquitin monomers and/or polymers.

6. The method according to claim 1 , wherein the second linkage-specific deubiquitinase has a linkage specificity which overlaps with that of the first linkage-specific deubiquitinase.

7. The method according to claim 1 , wherein the second linkage-specific deubiquitinase has a linkage specificity which does not overlap with that of the first linkage-specific deubiquitinase.

8. The method according to claim 2 , wherein ovarian tumour protease family deubiquitinase 1 (OTUD1) is used to cleave K63 linkages.

9. The method according to claim 2 , wherein ovarian tumour protease family deubiquitinase 4 (OTUD4) is used to cleave K48 linkages.

10. The method according to claim 2 , wherein ovarian tumour protease family deubiquitinase 3 (OTUD3) is used to cleave K6 and/or K11 linkages.

11. The method of claim 2 , wherein at least one of the first and second linkage-specific deubiquitinase has altered linkage specificity resulting from (a) addition or deletion of a UBD, or (b) mutation of the OTU S1′ site.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 2, 2018
From: MEDICAL RESEARCH COUNCIL
To: UNITED KINGDOM RESEARCH AND INNOVATION
Reel/Frame 046469/0108 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 15, 2014
From: MEVISSEN, TYCHO E.T.; HOSPENTHAL, MANUELA K.; KOMANDER, DAVID
To: MEDICAL RESEARCH COUNCIL
Reel/Frame 034506/0876 →